• Vaccine Name: Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004130
• Type: DNA vaccine
• Antigen: Multiple antigens from B. anthracis, Ebola virus, Marburg virus, and VEE virus were used. Specifically, this DNA vaccine includes Protective Antigen (PA) from B. anthracis, Glycoprotein (GP) and Nucleoprotein (NP) from Ebloa virus, Glycoprotein (GP) from Marburg virus strain Ravn, and 26S from VEE virus (Riemenschneider et al., 2003).
• PagA from Bacillus anthracis gene engineering:
  • Type: Recombinant protein preparation
  • Description: A DNA vaccine for the anthrax was made by PCR-amplifying the PA gene (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click Here.
• NP from Zaire ebolavirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: Ebola NP genes were cloned and the vaccine was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click Here.
• GP from Zaire ebolavirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: Ebola NP genes were cloned and the vaccine was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click Here.
• GP from Marburg virus Ravn gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Ravn GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Ci67strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• 26S mRNA from VEEV gene engineering:
  • Type: Recombinant protein preparation
  • Description: The vaccine for 26S mRNA was produced without additional signal sequence with the use of plasmid pWRG7077 (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005059
• Preparation: The necessary genes were inserted into expression plasmids following a cytomegalovirus immediate early promotor. MARV was procured through experiementally infected monkeys, then passed three times (Ravn) or one time(Musoke) in Vero cells. Inbred Strain 13 and outbred Hartley guinea pigs were injected subcutaneously with the vaccine. Responses were measured by IgG antibody ELISA with the use of cobalt-irradiated purified MARV in both strains. A study also included non-human primates, which underwent serum tests for viremia determination and blood chemistry(Riemenschneider et al., 2003).

Guinea pig Response

• Host Strain: Strain 13 and Hartley
• Vaccination Protocol: Gun-vaccinated guinea pigs were gene gun-vaccinated three (Musoke) or four (Ravn) times at 4-week intervals with approximately 2.5 μg of the MARV GP DNA (Riemenschneider et al., 2003).
• Persistence: Not noted.
• Immune Response: All of the MARV GP DNA-vaccinated guinea pigs developed antibodies to MARV(Riemenschneider et al., 2003).
• Side Effects: Not noted.
• Challenge Protocol: The challenge was a subcutaneous injection of 1000 plaque forming units (pfu) of homologous virus 4 weeks after the final vaccination for each guinea pig (Riemenschneider et al., 2003).
• Efficacy: Guinea pigs vaccinated with control DNA were viremic at day 7 post-challenge, as measured by plaque assay, and were infected by day 9. All guinea pigs vaccinated with the GP DNA vaccines were aviremic at day 7 and appreared healthy throughout the observation period(Riemenschneider et al., 2003).